HPV Vaccination Leads to Decreased Rates of Cervical Pre-Cancers


The human papillomavirus (HPV) vaccine reduces the incidence of pre-cancerous cervical intraepithelial neoplasia (CIN), according to a population-based study in New Mexico.

The human papillomavirus (HPV) vaccine reduces the incidence of pre-cancerous cervical intraepithelial neoplasia (CIN), according to a population-based study in New Mexico. The results of the study were published in JAMA Oncology.

The researchers examined rates of CIN in women between 15 and 29 years of age from 2007 to 2014 in the New Mexico HPV Pap Registry. CIN grade was evaluated with biopsies. After adjusting for cervical screening, the researchers saw significant reductions in the incidence of all grades of CIN among those aged 15 to 19 years. The annual decreases were 9% (P < .001), 10.5% (P = .03), and 41.3% (P = .05) for CIN1, CIN2, and CIN3, respectively. The reductions in CIN2 incidence in women aged 20 to 24 were also significant, decreasing annually by 6.3% (P = .02).

The New Mexico HPV Pap Registry is unique in that it is the only US-based surveillance database that has captured population estimates of both screening prevalence and rates of CIN since 2007, when nation-wide HPV vaccination was implemented.

“These data showing significant reductions in cervical pre-cancers represent the results from the overall population of young females, which includes those that are vaccinated and unvaccinated,” said study author Cosette M. Wheeler, PhD, of the department of pathology at the University of New Mexico Health Sciences Center, in a press release. “The data suggest that the age at which we begin cervical screening in the United States might be raised soon to age 25 as is already done in a number of other countries. Raising the age at which we begin cervical screening would be one of the first steps in integrating cervical screening and HPV vaccination, an important step in using healthcare dollars more effectively.”

In 2008, 48% of 13- to 17-year-old girls in New Mexico received at least one dose of the HPV vaccine and 17% received all three; by 2014, 59% of girls this age received at least one dose of the HPV vaccine, with 40% receiving all three.

The researchers suggest several factors that likely contributed to the reduced cervical pre-cancer rates: cross protection, or the vaccine’s ability to protect against additional types of HPV it does not target directly; efficacy of 1, 2, and 3 doses of the vaccine; and herd immunity.

Since the main goal of HPV vaccination is to prevent cervical cancer in women, the reductions in rates of CIN2 and CIN3 “are early benchmarks for achieving this aim,” wrote the study authors, while reductions in CIN1 are a “direct measure of reductions in HPV infections,” which are the necessary first step for virtually all cases of invasive cervical cancer. “Because CIN1 is the most common cervical neoplastic diagnosis that can lead to additional clinical follow-up, increased health care costs, and patient morbidities, reductions in CIN1 are an added benefit of HPV vaccination,” they wrote.

While current cervical screening guidelines recommend the same screening schedules for both unvaccinated and vaccinated women, based on this new analysis, the authors suggest that new guidelines be created that consider a later screening start for HPV vaccinated women.

Related Videos
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.
Related Content